Laboratory Correlates for a Phase II Trial of Romidepsin in Cutaneous and Peripheral T-Cell Lymphoma

Since romidepsin has shown promise in the treatment of T-cell lymphomas, we evaluated molecular endpoints gathered from 61 patients enrolled on a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma at the National Institutes of Health. The endpoints included histone H3 acetylati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bates, Susan E., Zhan, Zhirong, Steadman, Kenneth, Obrzut, Tomasz, Luchenko, Victoria, Frye, Robin, Robey, Robert W., Turner, Maria, Gardner, Erin R., Figg, William D., Steinberg, Seth M., Ling, Alex, Fojo, Tito, To, Kin Wah, Piekarz, Richard L.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2838427/
https://ncbi.nlm.nih.gov/pubmed/19874311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07954.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars